While there have been a smattering of biotech IPOs this year, med tech IPO activity has remained quiet. But that's changed quickly--with a $91 million IPO for precision medicine player NantHealth and another $50 million IPO for drug-device ophthalmic company Clearside Biomedical pricing on June 1.
Patrick Soon-Shiong's big data cancer analytics player NantHealth is making a run again at an IPO after it was delayed by a whistleblower suit.
Siemens has rebranded and will expand its Healthcare business. The imaging and laboratory diagnostics giant has, perhaps a bit awkwardly, rebranded the business as Siemens Healthineers. The group is a separately managed business within the larger corporate structure, a transition that happened early last year.
Royal Philips has big plans in HealthTech. But to execute on them, it needs to rid itself of its lighting businesses and, in the process, gain some liquidity to reinvest into health technology, which is expected to be the future of the transitioning industrial conglomerate that has traditionally spanned consumer, healthcare and lighting businesses.
The company markets a suite of breast imaging tools for personalized breast cancer screening based on objective measurements of volumetric breast density, compression and radiation dose.
InVentiv Group Holdings, one of the largest global contract research organizations in the world, is looking to float as part of its recent growth spurt.
More than a year ago, image-guided catheter-based systems company Avinger priced an upsized IPO at $13. Then it gained more than 80% in 2015. But this year has been far less kind to the Redwood City, CA-based company; its share price has fallen by more than half to less than $11, dipping well below the IPO price.
Hong Kong-based Hutchinson China MediTech announced this week it filed an amended F-1 form with the U.S. Securities and Exchange Commission for its planned $100 million IPO in which it plans to sell American depositary shares under the symbol HCM.
China Resources Pharmaceutical Group, part of the state-owned mega-corporation China Resources, is planning to tap the capital markets in Hong Kong for a $1 billion initial public offering, according to a report by Reuters.
Details on the initial public offering for Beijing-based biotech BeiGene are out with the offer topping the $100 million early estimate and insiders slated to take more than half in an offering that will be closely watched as sentiment gauge for other China-focused biotech firms into the U.S. market.